MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Levodopa(L-dopa)"

  • 2018 International Congress

    Efficacy and safety of safinamide as a levodopa adjunct in patients with parkinson disease and motor fluctuations: A systematic review of randomized controlled trials

    S. Hussain, A. Najmi (New Delhi, India)

    Objective: To assess the efficacy and safety of safinamide as an add-on therapy to levodopa in Parkinson patients. Background: Long-term use of levodopa is associated…
  • 2018 International Congress

    On Converting Patients From Oral Dopamine Agonists to the Carbidopa/Levodopa Enteral Suspension Method – Real World Conversion Ratios

    S. Nakano, L. Bahroo, F. Pagan, F. Amjad, S. Lo, I. Gambhir (Washington, D.C., DC, USA)

    Objective: To review guidelines for initiating Carbidopa/Levodopa Enteral Suspension method of delivery in the treatment of Parkinson’s Disease (PD) and to compare guidelines with real…
  • 2018 International Congress

    Impact of Dyskinesia in Parkinson’s Disease (PD) on Activities of Daily Living (ADLs) and Daily Tasks: Results from Pooled Phase 3 ADS-5102 Clinical Trials

    R. Pahwa, S. Isaacson, J. Jimenez-Shahed, I. Malaty, A. Deik, R. Gandhy, R. Johnson, R. Patni (Kansas City, KS, USA)

    Objective: To assess the impact of dyskinesias in PD on ADLs and the effects of ADS-5102 (amantadine) extended release capsules on these impairments. Background: ADS-5102…
  • 2018 International Congress

    Utility of Acute Levodopa Challenge Test In Early Parkinsonism

    M. Acharya, A. Biswas, G. Ganguly, S. Das (Kolkata, India)

    Objective: This prospective cohort study was conducted to evaluate the sensitivity and specificity of different outcomes of acute levodopa challenge test(ALCT) (motor improvement, development of…
  • 2018 International Congress

    Motor and non-motor symptoms of a 7.5-year prospective study of patients with Parkinson’s disease

    A. Yoritaka, Y. Shimo, T. Hatano, N. Hattori (Saitama, Japan)

    Objective: Previously, we retrospectively reported the prevalence and risks of motor and non-motor symptoms of a large number of patients (1453) with Parkinson’s disease (PD)…
  • 2018 International Congress

    Efficacy of ND0612 for nocturnal problems and early morning OFF

    F. Stocchi, W. Poewe, T. Rachmilewitz Minei, S. Oren, R. Case, K. Kieburtz, C. Olanow (Rome, Italy)

    Objective: ND012 is a drug-device combination delivering liquid L-dopa/carbidopa (LD/CD) via continuous SC infusion. This secondary analysis evaluated the efficacy of 2 dosing regimens (R1:…
  • 2018 International Congress

    Design of a Phase 3 Efficacy and Safety Trial of Accordion Pill™ Carbidopa/Levodopa for Parkinson’s Disease (PD) Patients Experiencing Motor Fluctuations

    P. LeWitt, R. Gendreau, J. Meckler, N. Navon (West Bloomfield, MI, USA)

    Objective: To review the design and unique features of an ongoing phase 3 trial of a gastric-retentive formulation of carbidopa/levodopa (CD/LD), the Accordion Pill™ (AP),…
  • 2018 International Congress

    Bdnf rs6265 and Other Variants Predict the Efficacy of Levodopa Monotherapy in Early-Stage Parkinson’s Disease

    C. Sortwell, P. Auinger, J. Goudreau, B. Pickut, M. Hacker, P. Charles, J. Lipton, A. Cole-Strauss, J. Elm, D. Fischer (Grand Rapids, MI, USA)

    Objective: To determine whether relatively prevalent variants in the gene for brain-derived neurotrophic factor (Bdnf) are associated with differential efficacy of levodopa or other dopaminergic…
  • 2018 International Congress

    Using saccades as an early test of levodopa treatment in Parkinson’s Disease

    Z.J. Lu, S. Dillon, P. Zetegren, M. Brzezick, C. Kennard, J. FitzGerald, C. (Oxford, United Kingdom)

    Objective: It is important to know what potential confounding effects the medications used to treat Parkinson’s disease (PD) have on eye movement, in order to…
  • 2018 International Congress

    Efficacy of liquid sinemet on non-motor symptoms in Parkinson’s disease

    M. Danoudis, R. Iansek, C. Boon (Cheltenham, Australia)

    Objective: To investigate the short term effect of liquid sinemet on the non-motor symptoms of people with advanced Parkinson’ disease (PD) who experience complex motor…
  • « Previous Page
  • 1
  • …
  • 40
  • 41
  • 42
  • 43
  • 44
  • …
  • 62
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley